Andrew Tutt
Institute of Cancer Research, United Kingdom · Guy's Hospital, Great Maze Pond, London. · Integrated Cancer Centre Guy's Hospital, King's College, London School of Medicine, London, UK
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Tutt as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03740893 · PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerInstitute of Cancer Research, United Kingdom · recruiting · Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD · principal investigator
- Ph2NCT03330847 · To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZeneca · active not recruiting · Metastatic Triple Negative Breast Cancer · principal investigator
- Ph3NCT02032823 · Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerAstraZeneca · active not recruiting · Breast Cancer · principal investigator
- Ph3NCT00532727 · Triple Negative Breast Cancer TrialInstitute of Cancer Research, United Kingdom · unknown · Breast Cancer · principal investigator
- Ph2NCT00494234 · Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast CancerAstraZeneca · completed · Breast Neoplasms · principal investigator
- Ph2NCT00494442 · Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian CancerAstraZeneca · completed · Ovarian Neoplasm · principal investigator
- Ph2NCT00321633 · Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast CancerUniversity College London Hospitals · completed · brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:10 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 1,430 citationsRCR 31.5
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med · 20211,410 citationsRCR 78.5
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Nat Med · 2018721 citationsRCR 23.2
- 399 citationsRCR 26.2
- Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.Nat Commun · 2020215 citationsRCR 7.7
- 17 citationsRCR 1.5
- Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.Breast Cancer · 202315 citationsRCR 1.1
- Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.Breast Cancer Res Treat · 20144 citationsRCR 0.1